Modern men's health, engineered.
Men's health is the largest underaddressed therapeutic category in global pharmaceutical markets. The numbers — across life expectancy, disease prevalence, and healthcare engagement — are not subtle.
Global life expectancy at birth: 71 years for men, 76 for women. A gap that has been consistent since 1950.
WHO · 2023
Some degree of erectile dysfunction in men aged 40–70, rising from 40% at age 40 to 70% by age 70.
Massachusetts Male Aging Study
Average global gap between lifespan and healthspan across 183 WHO member states — and widening since 2000.
WHO GHO · Mayo Clinic 2024
Men in high-income countries die by suicide at approximately three times the rate of women.
World Health Organization
Pooled global prevalence of erectile dysfunction in diabetic men — where the NCD burden is fastest-growing.
BMC Public Health · 2024
Of all deaths from occupational risks globally are male. Men carry disproportionate workplace mortality.
Global Burden of Disease
IMMANX is QuadroPharma's dedicated men's health division. We engineer, manufacture, and partner-distribute a focused portfolio across the male wellness spectrum — beginning with sexual wellness through IMBOLDX and extending into testosterone support, sleep, focus, and longevity.
Live products
Categories — Rx & OTC
Registered cGMP
Distribution markets
Every IMMANX product is live and available for distributor partnerships. Three prescription jellies, three OTC nutraceuticals — all manufactured to pharmaceutical-grade cGMP standards, all carrying the same brand system.
Every IMMANX product is manufactured under the same pharmaceutical standards. Our infrastructure is built to scale across the portfolio — not to be re-validated with every new SKU.
A single accredited manufacturing site for the entire IMMANX portfolio. Every product inherits the same facility, the same compliance posture, the same audit trail.
Active pharmaceutical ingredients managed under International Council for Harmonisation guidelines. Full master file shared across distributor submissions.
Residual solvent testing per United States Pharmacopeia chapter 467. Documented per batch, per product, per shipment.
Track-and-trace barcodes on every outer carton across the portfolio. Distributors and regulators can verify batch lineage from manufacturer to pharmacy.
When a new IMMANX product enters production, it inherits our complete quality infrastructure — same facility, same testing protocols, same traceability standards. That's how we add SKUs without adding risk.
Single FDA-registered facility across the entire portfolio. New products inherit existing validation rather than recommissioning.
High-performance liquid chromatography on every production batch. Documented dose accuracy on the certificate of analysis.
Long-term and accelerated stability studies per ICH Q1A guidelines. Shelf-life claims supported by real data, not extrapolation.
GS1-128 codes on every outer carton across all products. Distributor partners can verify lineage end-to-end.
Master file architecture that allows new products to slot into existing distributor submissions, accelerating territory expansion.
Full ICH Q7 documentation available to qualified distributor partners under standard NDA. No regulatory surprises mid-relationship.
An IMMANX distributor relationship is built to compound. The infrastructure you set up for IMBOLDX is the same infrastructure that handles every product after it.
New IMMANX products fall under your existing distribution agreement. Renegotiation only when geography changes, not when the catalog grows.
One IMMANX commercial team handles your entire product portfolio. No silos between IMBOLDX, IMRISEX, or anything that follows.
Per-territory submissions are designed to span the portfolio. Adding a new product means an amendment, not a fresh filing from zero.
Cross-product volume discounts and incentive structures. Volume scales across SKUs, not just within one.
Brand asset libraries delivered per product — logos, pack mockups, distributor-facing spec sheets, and HCP detail aids.
Qualified distributor partners receive priority access to new IMMANX products as the portfolio expands — same agreement, same brand system, no new contract negotiation.
For distributor partnerships, manufacturing inquiries, sampling, or any commercial conversation about the IMMANX portfolio.
Modern men's health, engineered.
Pharmaceutical and nutraceutical R&D, USA cGMP manufacturing, and global B2B distribution. IMMANX is the men's health division of QuadroPharma.
QuadroPharma Inc
280 Moon Clinton Rd
Moon Township
PA 15108, USA
QuadroPharma FZ LLC
Unit 452, Level 3, The Offices 3
One Central, DWTC
Sheikh Zayed Road
Dubai, UAE
© 2026 QuadroPharma. All rights reserved.
Pharmaceutical product